ApconiX

ApconiX specializes in integrating toxicology and ion channel expertise to enhance drug safety. It's designed for pharmaceutical companies seeking to make informed decisions throughout the drug development process. The service targets nonclinical safety and risk reduction, ensuring drugs are safe from early development to market approval.

Key Features:

• Toxicology and DMPK Consultancy: Offers flexible access to experienced scientists who provide strategic advice on drug metabolism and pharmacokinetics.

• Safety Science: Combines toxicology expertise with advanced data science to assess and mitigate safety risks effectively.

• Ion Channel Screening: Provides customizable screening services tailored to specific needs and timelines, crucial for evaluating drug interactions with ion channels.

ApconiX's team includes experts with over 500 years of combined experience in drug discovery and development. They cover all major safety disciplines and offer bespoke assay development for specific safety assessments, including hERG, CiPA, and seizure liability.

The service is ideal for companies needing comprehensive safety assessments, including target, modality, and therapeutic asset evaluations. ApconiX's approach focuses on increasing asset value by understanding and reducing safety risks, making it a valuable resource for informed decision-making in drug safety.